Cargando…

Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic

Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods: A retrospective quasi-experimental before–after study was conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Grau, Santiago, Echeverria-Esnal, Daniel, Gómez-Zorrilla, Silvia, Navarrete-Rouco, Maria Eugenia, Masclans, Joan Ramon, Espona, Merce, Gracia-Arnillas, Maria Pilar, Duran, Xavier, Comas, Merce, Horcajada, Juan Pablo, Ferrández, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911440/
https://www.ncbi.nlm.nih.gov/pubmed/33573070
http://dx.doi.org/10.3390/antibiotics10020132
_version_ 1783656342242721792
author Grau, Santiago
Echeverria-Esnal, Daniel
Gómez-Zorrilla, Silvia
Navarrete-Rouco, Maria Eugenia
Masclans, Joan Ramon
Espona, Merce
Gracia-Arnillas, Maria Pilar
Duran, Xavier
Comas, Merce
Horcajada, Juan Pablo
Ferrández, Olivia
author_facet Grau, Santiago
Echeverria-Esnal, Daniel
Gómez-Zorrilla, Silvia
Navarrete-Rouco, Maria Eugenia
Masclans, Joan Ramon
Espona, Merce
Gracia-Arnillas, Maria Pilar
Duran, Xavier
Comas, Merce
Horcajada, Juan Pablo
Ferrández, Olivia
author_sort Grau, Santiago
collection PubMed
description Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods: A retrospective quasi-experimental before–after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0.014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April–May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0.029), carbapenems (p = 0.002), daptomycin (p = 0.002), azithromycin (p = 0.030), and linezolid (p = 0.011) but followed a similar temporal pattern. Conclusion: An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes.
format Online
Article
Text
id pubmed-7911440
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79114402021-02-28 Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic Grau, Santiago Echeverria-Esnal, Daniel Gómez-Zorrilla, Silvia Navarrete-Rouco, Maria Eugenia Masclans, Joan Ramon Espona, Merce Gracia-Arnillas, Maria Pilar Duran, Xavier Comas, Merce Horcajada, Juan Pablo Ferrández, Olivia Antibiotics (Basel) Article Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods: A retrospective quasi-experimental before–after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0.014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April–May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0.029), carbapenems (p = 0.002), daptomycin (p = 0.002), azithromycin (p = 0.030), and linezolid (p = 0.011) but followed a similar temporal pattern. Conclusion: An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes. MDPI 2021-01-29 /pmc/articles/PMC7911440/ /pubmed/33573070 http://dx.doi.org/10.3390/antibiotics10020132 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grau, Santiago
Echeverria-Esnal, Daniel
Gómez-Zorrilla, Silvia
Navarrete-Rouco, Maria Eugenia
Masclans, Joan Ramon
Espona, Merce
Gracia-Arnillas, Maria Pilar
Duran, Xavier
Comas, Merce
Horcajada, Juan Pablo
Ferrández, Olivia
Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title_full Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title_fullStr Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title_full_unstemmed Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title_short Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic
title_sort evolution of antimicrobial consumption during the first wave of covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911440/
https://www.ncbi.nlm.nih.gov/pubmed/33573070
http://dx.doi.org/10.3390/antibiotics10020132
work_keys_str_mv AT grausantiago evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT echeverriaesnaldaniel evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT gomezzorrillasilvia evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT navarreteroucomariaeugenia evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT masclansjoanramon evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT esponamerce evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT graciaarnillasmariapilar evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT duranxavier evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT comasmerce evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT horcajadajuanpablo evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic
AT ferrandezolivia evolutionofantimicrobialconsumptionduringthefirstwaveofcovid19pandemic